Abstract
Cardiovascular disease (CVD) accounts for almost 75% of mortality in subjects with type 2 diabetes (T2DM). The relationship between hypertension, dyslipidaemia and CVD is now well established. However, the precise link between glycaemia and macrovascular complications has remained unclear. There is now emerging evidence that postprandial glucose (PPG) contributes significantly to CVD risk, although to date there are no large scale interventional studies underway which test the hypothesis that targeting PPG will reduce CVD risk. Until recently, there was no consensus about the definition of postprandial hyperglycaemia. The International Diabetes Federation (IDF) has now developed new clinical guidelines for postprandial glucose and recommend that 2-hour post meal glucose levels are kept < 7.8 mmol/L. In the last few years more has become known about the cellular mechanisms triggered in response to glucose excursions which may explain this increased susceptibility to CVD. Recently, investigation into the contribution of PPG to HbA1c in subjects with T2DM, has shown that this is maximal in relatively well controlled diabetic subjects. Hence PPG is emerging as a legitimate therapeutic target to minimise CVD risk. This review addresses the evidence linking postprandial hyperglycaemia to cardiovascular disease, the cellular mechanisms explaining this enhanced risk and a therapeutic strategy to address postprandial glucose excursions.
Keywords: Cardiovascular disease, postprandial glucose, postprandial hyperglycaemia, diabetes, cellular mechanism, all cause mortality
Current Vascular Pharmacology
Title: Postprandial Glucose - A Potential Therapeutic Target to Reduce Cardiovascular Mortality
Volume: 7 Issue: 1
Author(s): Raj Peter, Onyebuchi E. Okoseime, Alan Rees and David R. Owens
Affiliation:
Keywords: Cardiovascular disease, postprandial glucose, postprandial hyperglycaemia, diabetes, cellular mechanism, all cause mortality
Abstract: Cardiovascular disease (CVD) accounts for almost 75% of mortality in subjects with type 2 diabetes (T2DM). The relationship between hypertension, dyslipidaemia and CVD is now well established. However, the precise link between glycaemia and macrovascular complications has remained unclear. There is now emerging evidence that postprandial glucose (PPG) contributes significantly to CVD risk, although to date there are no large scale interventional studies underway which test the hypothesis that targeting PPG will reduce CVD risk. Until recently, there was no consensus about the definition of postprandial hyperglycaemia. The International Diabetes Federation (IDF) has now developed new clinical guidelines for postprandial glucose and recommend that 2-hour post meal glucose levels are kept < 7.8 mmol/L. In the last few years more has become known about the cellular mechanisms triggered in response to glucose excursions which may explain this increased susceptibility to CVD. Recently, investigation into the contribution of PPG to HbA1c in subjects with T2DM, has shown that this is maximal in relatively well controlled diabetic subjects. Hence PPG is emerging as a legitimate therapeutic target to minimise CVD risk. This review addresses the evidence linking postprandial hyperglycaemia to cardiovascular disease, the cellular mechanisms explaining this enhanced risk and a therapeutic strategy to address postprandial glucose excursions.
Export Options
About this article
Cite this article as:
Peter Raj, Okoseime E. Onyebuchi, Rees Alan and Owens R. David, Postprandial Glucose - A Potential Therapeutic Target to Reduce Cardiovascular Mortality, Current Vascular Pharmacology 2009; 7 (1) . https://dx.doi.org/10.2174/157016109787354169
DOI https://dx.doi.org/10.2174/157016109787354169 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diagnosis and Management of Diabetes and the Relationship of dGlucose to Kidney Function
Current Diabetes Reviews Aqueous Humor Pharmacokinetics of Dorzolamide Loaded PLGAChitosan Nanoparticles by Ultra Performance Liquid Chromatography
Current Pharmaceutical Analysis Dissecting the Mechanisms of Thrombogenesis and Atherosclerosis for Neurodegenerative Disorders
Current Neurovascular Research An Optimal Combination of Chemically Pure Compounds from <i>Salvia miltiorrhiza</i> for Inhibiting Cell Proliferation
Cardiovascular & Hematological Agents in Medicinal Chemistry Association between Apo B Levels in Mothers and in their Pre-school Age Offspring
Cardiovascular & Hematological Agents in Medicinal Chemistry Clinical Management of Diabetes Mellitus in the Older Adult Patient
Current Diabetes Reviews The Relevance of Long-Term Adherence to Non-Pharmacological and Pharmacological Treatment of Hypertension
Current Hypertension Reviews Molecular Basis of Cardioprotection by Erythropoietin
Current Molecular Pharmacology Evaluation of Plasma Homocysteine Levels as a Prognostic Factor for the Occurrence of Perioperative Myocardial Infarction in Coronary Artery Bypass Grafting: A Pilot Study
Vascular Disease Prevention (Discontinued) The Emerging Role of Complement C3 as A Biomarker of Insulin Resistance and Cardiometabolic Diseases: Preclinical and Clinical Evidence
Reviews on Recent Clinical Trials The Phenotypic and Metabolic Characteristics of Neutrophils in Normal Pregnancy and Preeclampsia
Current Immunology Reviews (Discontinued) Ventilatory Support in Persistent Pulmonary Hypertension of the Newborn
Current Respiratory Medicine Reviews Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Determination of Interchangeability of Different Brands of Diclofenac Sodium Sustained Release Tablets in Healthy Subjects Using Pharmacokinetic End Points
Letters in Drug Design & Discovery Cardiovascular Toxicity of Cyclooxygenase Inhibitors and Promising Natur a l Substitutes
Current Pharmaceutical Design The Pulmonary Renin-Angiotensin System
Current Pharmaceutical Design Inflammation as Therapeutic Objective in Stroke
Current Pharmaceutical Design Calcimimetic Drugs and Biomarkers
Recent Patents on Biomarkers Present Insights on Cardiomyopathy in Diabetic Patients
Current Diabetes Reviews Long-Term Metabolic Consequences in Patients with a History of Gestational Diabetes
Current Pharmaceutical Design